Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2023 Earnings Results

Crinetics Pharmaceuticals Misses on EPS — Stock Down 0.93%

Crinetics Pharmaceuticals reported a loss that was slightly worse than expected, which contributed to a modest decline in the stock price. Investors may be concerned about the lack of revenue information and the absence of guidance for future performance. The stock's reaction reflects cautious sentiment in light of the company's current challenges and management's defensive tone.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.85	N/A	-3.41%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over current performance but highlighted their commitment to addressing operational issues. They did not provide specific guidance for future quarters.

Management acknowledged the challenges faced during the quarter.

They emphasized ongoing efforts to improve operational efficiency.

Future plans were discussed, but no specific guidance was provided.

Crinetics Pharmaceuticals Misses on EPS — Stock Down 0.93%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS — Stock Down 0.93%

Key numbers

Management commentary